How to buy Neurocrine Biosciences stock

Neurocrine Biosciences, Inc is a biotechnology business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Neurocrine Biosciences employs 845 staff and has a trailing 12-month revenue of around 0.00.

Neurocrine Biosciences share price

Use our graph to track the performance of NBIX stocks over time.

Neurocrine Biosciences shares at a glance

• Key figures

Information last updated 2021-04-23.

52-week range	$86.02 - $136.27
50-day moving average	$94.21
200-day moving average	$100.12
Wall St. target price	$126.86
PE ratio	23.1995
Dividend yield	N/A (0%)
Earnings per share (TTM)	$4.16

Buy Neurocrine Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Neurocrine Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Neurocrine Biosciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Neurocrine Biosciences under- or over-valued?

Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Neurocrine Biosciences's P/E ratio

Neurocrine Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Neurocrine Biosciences shares trade at around 23x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Neurocrine Biosciences's PEG ratio

Neurocrine Biosciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.87. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Neurocrine Biosciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Neurocrine Biosciences's EBITDA

Neurocrine Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $336.1 million.

The EBITDA is a measure of a Neurocrine Biosciences's overall financial performance and is widely used to measure a its profitability.

Neurocrine Biosciences financials

Revenue TTM	$1 billion
Operating margin TTM	31.31%
Gross profit TTM	$760.8 million
Return on assets TTM	13.46%
Return on equity TTM	46.2%
Profit margin	38.94%
Book value	$12.05
Market capitalisation	$9.1 billion

TTM: trailing 12 months

Shorting Neurocrine Biosciences shares

There are currently 7.0 million Neurocrine Biosciences shares held short by investors – that's known as Neurocrine Biosciences's "short interest". This figure is 57.1% up from 4.5 million last month.

There are a few different ways that this level of interest in shorting Neurocrine Biosciences shares can be evaluated.

Neurocrine Biosciences's "short interest ratio" (SIR)

Neurocrine Biosciences's "short interest ratio" (SIR) is the quantity of Neurocrine Biosciences shares currently shorted divided by the average quantity of Neurocrine Biosciences shares traded daily (recently around 1.9 million). Neurocrine Biosciences's SIR currently stands at 3.65. In other words for every 100,000 Neurocrine Biosciences shares traded daily on the market, roughly 3650 shares are currently held short.

However Neurocrine Biosciences's short interest can also be evaluated against the total number of Neurocrine Biosciences shares, or, against the total number of tradable Neurocrine Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neurocrine Biosciences's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Neurocrine Biosciences shares in existence, roughly 70 shares are currently held short) or 0.075% of the tradable shares (for every 100,000 tradable Neurocrine Biosciences shares, roughly 75 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neurocrine Biosciences.

Find out more about how you can short Neurocrine Biosciences stock.

Neurocrine Biosciences share dividends

We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.

Neurocrine Biosciences share price volatility

Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $86.02 up to $136.265. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.7865. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).

Neurocrine Biosciences overview

Neurocrine Biosciences, Inc. , a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1. 6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for the treatment of rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for the treatment of anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.

Frequently asked questions

• What percentage of Neurocrine Biosciences is owned by insiders or institutions?

  Currently 1.14% of Neurocrine Biosciences shares are held by insiders and 98.416% by institutions.

• How many people work for Neurocrine Biosciences?

  Latest data suggests 845 work at Neurocrine Biosciences.

• When does the fiscal year end for Neurocrine Biosciences?

  Neurocrine Biosciences's fiscal year ends in December.

• Where is Neurocrine Biosciences based?

  Neurocrine Biosciences's address is: 12780 El Camino Real, San Diego, CA, United States, 92130

• What is Neurocrine Biosciences's ISIN number?

  Neurocrine Biosciences's international securities identification number is: US64125C1099

• What is Neurocrine Biosciences's CUSIP number?

  Neurocrine Biosciences's Committee on Uniform Securities Identification Procedures number is: 64125C109